drugset / Trial / NCT05651100
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Phase 1/2
Unknown
50 enrolled
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the efficacy and safety of Sequential CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma.
Timeline
- Start
- 2022-12-10
- Primary completion
- 2024-12-10
- Completion
- 2025-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 and CD22 targeted CAR-T cells | Cell therapy | — | Other |